Advertisement
Atherosclerosis
Advanced SearchSave search
Full length article| Volume 241, ISSUE 1, P176-182, July 01, 2015

Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis

Published:May 16, 2015DOI:https://doi.org/10.1016/j.atherosclerosis.2015.05.006
Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis
Previous ArticlePrevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology
Next ArticleOxidative stress and paraoxonase 1 status in acute ischemic stroke patients

      Highlights

      • •
        We evaluated associations of Lp-PLA2 and first-time cardiovascular events.
      • •
        Participants comprised a multi-ethnic cohort characterized at baseline for subclinical disease.
      • •
        Both Lp-PLA2 activity and mass were associated with incident cardiovascular events.
      • •
        Associations of Lp-PLA2 activity were weaker in Chinese participants.
      • •
        There was no confounding by subclinical atherosclerosis measures.

      Abstract

      Objective

      Prospective studies reporting a positive association of lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity with incident cardiovascular disease (CVD) have included primarily white individuals. We evaluated associations of Lp-PLA2 and first-time cardiovascular events in a healthy multi-ethnic cohort characterized by presence or absence of baseline subclinical atherosclerosis.

      Methods

      Lp-PLA2 mass and activity were measured at baseline in 5456 participants in the Multi-Ethnic Study of Atherosclerosis. Individuals were characterized for presence of baseline subclinical disease (coronary artery calcium score > 0 or carotid intima-media thickness value > 80th percentile) and followed prospectively for development of CVD events (coronary heart disease, ischemic stroke, and cardiovascular death).

      Results

      516 incident CVD events occurred over median follow-up of 10.2 years. In adjusted Cox proportional hazards models, each higher standard deviation of both Lp-PLA2 activity and mass was associated with an increased risk of cardiovascular events; hazard ratios (HR; 95% confidence intervals (CI)) 1.12 (1.01–1.26) for Lp-PLA2 activity and 1.10 (1.01–1.21) for mass. Associations did not differ by subclinical disease status (p-value for interaction 0.99 for Lp-PLA2 activity and 0.32 for Lp-PLA2 mass) and there was no confounding by subclinical atherosclerosis measures. Associations of Lp-PLA2 activity but not mass were weaker in Chinese participants but there were relatively few events among Chinese in race-stratified analysis.

      Conclusion

      In this multi-ethnic cohort, Lp-PLA2 was positively associated with CVD risk, regardless of the presence of coronary artery calcium or a thickened carotid-intimal media.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Häkkinen T.
        • Luoma J.S.
        • Hiltunen M.O.
        • Macphee C.H.
        • Milliner K.J.
        • Patel L.
        • Rice S.Q.
        • Tew D.G.
        • Karkola K.
        • Ylä-Herttuala S.
        Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions.
        Arterioscler. Thromb. Vasc. Biol. 1999; 19: 2909-2917
        View in Article
        • Kolodgie F.D.
        • Burke A.P.
        • Skorija K.S.
        • Ladich E.
        • Kutys R.
        • Makuria A.T.
        • Virmani R.
        Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis.
        Arterioscler. Thromb. Vasc. Biol. 2006; 26: 2523-2529
        View in Article
        • MacPhee C.H.
        • Moores K.E.
        • Boyd H.F.
        • Dhanak D.
        • Ife R.J.
        • Leach C.A.
        • Leake D.S.
        • Milliner K.J.
        • Patterson R.A.
        • Suckling K.E.
        • Tew D.G.
        • Hickey D.M.
        Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.
        Biochem. J. 1999; 338: 479-487
        View in Article
        • Rosenson R.S.
        • Stafforini D.M.
        Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.
        J. Lipid Res. 2012; 53 (epub ahead of print): 1767-1782
        View in Article
        • Weintraub H.S.
        Identifying the vulnerable patient with rupture-prone plaque.
        Am. J. Cardiol. 2008; 101: 3F-10F
        View in Article
        • Winkler K.
        • Winkelmann B.R.
        • Scharnagl H.
        • Hoffmann M.M.
        • Grawitz A.B.
        • Nauck M.
        • Böhm B.O.
        • März W.
        Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
        Circulation. 2005; 111: 980-987
        View in Article
        • Thompson A.
        • Gao P.
        • Orfei L.
        • Watson S.
        • Di Angelantonio E.
        • Kaptoge S.
        • Ballantyne C.
        • Cannon C.P.
        • Criqui M.
        • Cushman M.
        • Hofman A.
        • Packard C.
        • Thompson S.G.
        • Collins R.
        • Danesh J.
        Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.
        Lancet. 2011; 375: 1536-1544
        View in Article
        • Oei H.H.
        • van der Meer I.M.
        • Hofman A.
        • Koudstaal P.J.
        • Stijnen T.
        • Breteler M.M.
        • Witteman J.C.
        Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
        Circulation. 2005; 111: 570-575
        View in Article
        • Packard C.J.
        • O'Reilly D.S.
        • Caslake M.J.
        • McMahon A.D.
        • Ford I.
        • Cooney J.
        • Macphee C.H.
        • Suckling K.E.
        • Krishna M.
        • Wilkinson F.E.
        • Rumley A.
        • Lowe G.D.
        Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
        N. Engl. J. Med. 2000; 343: 1148-1155
        View in Article
        • Ballantyne C.M.
        • Hoogeveen R.C.
        • Bang H.
        • Coresh J.
        • Folsom A.R.
        • Heiss G.
        • Sharrett A.R.
        Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
        Circulation. 2004; 109: 837-842
        View in Article
        • Ballantyne C.M.
        • Hoogeveen R.C.
        • Bang H.
        • Coresh J.
        • Folsom A.R.
        • Chambless L.E.
        • Myerson M.
        • Wu K.K.
        • Sharrett A.R.
        • Boerwinkle E.
        Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
        Arch. Intern Med. 2005; 165: 2479-2484
        View in Article
        • Koenig W.
        • Khuseyinova N.
        • Lowel H.
        • Trischler G.
        • Meisinger C.
        Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
        Circulation. 2004; 110: 1903-1908
        View in Article
        • Folsom A.R.
        • Kronmal R.A.
        • Detrano R.C.
        • O'Leary D.H.
        • Bild D.E.
        • Bluemke D.A.
        • Budoff M.J.
        • Liu K.
        • Shea S.
        • Szklo M.
        • Tracy R.P.
        • Watson K.E.
        • Burke G.L.
        Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA).
        Arch. Intern Med. 2008; 168: 1333-1339
        View in Article
        • White H.D.
        • Held C.
        • Stewart R.
        • Tarka E.
        • Brown R.
        • Davies R.Y.
        • Budaj A.
        • Harrington R.A.
        • Steg P.G.
        • Ardissino D.
        • Armstrong P.W.
        • Avezum A.
        • Aylward P.E.
        • Bryce A.
        • Chen H.
        • Chen M.F.
        • Corbalan R.
        • Dalby A.J.
        • Danchin N.
        • De Winter R.J.
        • Denchev S.
        • Diaz R.
        • Elisaf M.
        • Flather M.D.
        • Goudev A.R.
        • Granger C.B.
        • Grinfeld L.
        • Hochman J.S.
        • Husted S.
        • Kim H.S.
        • Koenig W.
        • Linhart A.
        • Lonn E.
        • López-Sendón J.
        • Manolis A.J.
        • Mohler 3rd, E.R.
        • Nicolau J.C.
        • Pais P.
        • Parkhomenko A.
        • Pedersen T.R.
        • Pella D.
        • Ramos-Corrales M.A.
        • Ruda M.
        • Sereg M.
        • Siddique S.
        • Sinnaeve P.
        • Smith P.
        • Sritara P.
        • Swart H.P.
        • Sy R.G.
        • Teramoto T.
        • Tse H.F.
        • Watson D.
        • Weaver W.D.
        • Weiss R.
        • Viigimaa M.
        • Vinereanu D.
        • Zhu J.
        • Cannon C.P.
        • Wallentin L.
        Darapladib for preventing ischemic events in stable coronary heart disease.
        N. Engl. J. Med. 2014; 370: 1702-1711
        View in Article
        • Bild D.E.
        • Bluemke D.A.
        • Burke G.L.
        • Detrano R.
        • Diez Roux A.V.
        • Folsom A.R.
        • Greenland P.
        • Jacob Jr., D.R.
        • Kronmal R.
        • Liu K.
        • Nelson J.C.
        • O'Leary D.
        • Saad M.F.
        • Shea S.
        • Szklo M.
        • Tracy R.P.
        Multi-ethnic study of atherosclerosis: objectives and design.
        Am. J. Epidemiol. 2002; 156: 871-881
        View in Article
        • Ramsey 3rd, M.
        Blood pressure monitoring: automated oscillometric devices.
        J. Clin. Monit. 1991; 7: 56-67
        View in Article
        • Lenzini L.
        • Antezza K.
        • Caroccia B.
        • Wolfert R.L.
        • Szczech R.
        • Cesari M.
        • Narkiewicz K.
        • Williams C.J.
        • Rossi G.P.
        A twin study of heritability of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity.
        Atherosclerosis. 2009; 205: 181-185
        View in Article
        • Carr J.J.
        • Nelson J.C.
        • Wong N.D.
        • McNitt-Gray M.
        • Arad Y.
        • Jacobs Jr., D.R.
        • Sidney S.
        • Bild D.E.
        • Williams O.D.
        • Detrano R.C.
        Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study.
        Radiology. 2005; 234: 35-43
        View in Article
        • Agatston A.S.
        • Janowitz W.R.
        • Hildner F.J.
        • Zusmer N.R.
        • Viamonte Jr., M.
        • Detrano R.
        Quantification of coronary artery calcium using ultrafast computed tomography.
        J. Am. Coll. Cardiol. 1990; 15: 827-832
        View in Article
        • O'Leary D.H.
        • Polak J.F.
        • Wolfson Jr., S.K.
        • Bond M.G.
        • Bommer W.
        • Sheth S.
        • Psaty B.M.
        • Sharrett A.R.
        • Manolio T.A.
        Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group.
        Stroke; a J. Cereb. Circulation. 1991; 22: 1155-1163
        View in Article
        • Blake G.J.
        • Dada N.
        • Fox J.C.
        • Manson J.E.
        • Ridker P.M.
        A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women.
        J. Am. Coll. Cardiol. 2001; 38: 1302-1306
        View in Article
        • Persson M.
        • Hedblad B.
        • Nelson J.J.
        • Berglund G.
        Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
        Arterioscler. Thromb. Vasc. Biol. 2007; 27: 1411-1416
        View in Article
        • Daniels L.B.
        • Laughlin G.A.
        • Sarno M.J.
        • Bettencourt R.
        • Wolfert R.L.
        • Barrett-Connor E.
        Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.
        J. Am. Coll. Cardiol. 2008; 51: 913-919
        View in Article
        • Hou L.
        • Chen S.
        • Yu H.
        • Lu X.
        • Chen J.
        • Wang L.
        • Huang J.
        • Fan Z.
        • Gu D.
        Associations of PLA2G7 gene polymorphismis with plasa lipoprotien-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing Atherosclerosis Study.
        Hum. Genet. 2009; 125: 111-120
        View in Article
        • Stafforini D.M.
        • Satoh K.
        • Atkinson D.L.
        • Tjoelker L.W.
        • Eberhardt C.
        • Yoshida H.
        • Imaizumi T.
        • Takamatsu S.
        • Zimmerman G.A.
        • McIntyre T.M.
        • Gray P.W.
        • Prescott S.M.
        Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase.
        J. Clin. Investig. 1996; 97: 2784-2791
        View in Article
        • Miwa M.
        • Miyake T.
        • Yamanaka T.
        • Sugatani J.
        • Suzuki Y.
        • Sakata S.
        • Araki Y.
        • Matsumoto M.
        Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children.
        J. Clin. Investig. 1988; 82: 1983-1991
        View in Article
        • Jang Y.
        • Kim O.Y.
        • Koh S.J.
        • Chae J.S.
        • Ko Y.G.
        • Kim J.Y.
        • Cho H.
        • Jeong T.S.
        • Lee W.S.
        • Ordovas J.M.
        • Lee J.H.
        The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men.
        J. Clin. Endocrinol. Metab. 2006; 91: 3521-3527
        View in Article
        • Yamada Y.
        • Yoshida H.
        • Ichihara S.
        • Imaizumi T.
        • Satoh K.
        • Yokota M.
        Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population.
        Atherosclerosis. 2000; 150: 209-216
        View in Article
        • Casas J.P.
        • Ninio E.
        • Panayiotou A.
        • Palmen J.
        • Cooper J.A.
        • Ricketts S.L.
        • Sofat R.
        • Nicolaides A.N.
        • Corsetti J.P.
        • Fowkes F.G.
        • Tzoulaki I.
        • Kumari M.
        • Brunner E.J.
        • Kivimaki M.
        • Marmot M.G.
        • Hoffmann M.M.
        • Winkler K.
        • März W.
        • Ye S.
        • Stirnadel H.A.
        • Boekholdt S.M.
        • Khaw K.T.
        • Humphries S.E.
        • Sandhu M.S.
        • Hingorani A.D.
        • Talmud P.J.
        PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.
        Circulation. 2010; 121: 2284-2293
        View in Article
        • Jang Y.
        • Waterworth D.
        • Lee J.E.
        • et al.
        Carriage of the V279F null allele within the gene encoding Lp-PLA(2) is protective from coronary artery disease in South Korean males.
        PLoS One. 2011; 6: e18208
        View in Article
        • Liu X.
        • Zhu R.
        • Tian Y.
        • Li Q.
        • Li L.
        • Deng S.
        • He Z.
        Association of PLA2G7 gene polymorphisms with ischemic stroke in northern Chinese Han population.
        Clin. Biochem. 2014; 47: 404-408
        View in Article
        • Grallert H.
        • Dupuis J.
        • Bis J.C.
        • et al.
        Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.
        Eur. Heart J. 2012; 33: 238-251
        View in Article
        • Cao J.J.
        • Arnold A.M.
        • Manolio T.A.
        • Polak J.F.
        • Psaty B.M.
        • Hirsch C.H.
        • Kuller L.H.
        • Cushman M.
        Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study.
        Circulation. 2007; 116: 32-38
        View in Article
        • Furberg C.D.
        • Nelson J.J.
        • Solomon C.
        • Cushman M.
        • Jenny N.S.
        • Psaty B.M.
        Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study.
        J. Am. Geriatr. Soc. 2008; 56: 792-799
        View in Article
        • Persson M.
        • Nilsson J.
        • Nelson J.J.
        • Hedblad B.
        • Berglund G.
        The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort.
        Atherosclerosis. 2007; 190: 388-396
        View in Article
        • Campo S.
        • Sardo M.A.
        • Bitto A.
        • Bonaiuto A.
        • Trimarchi G.
        • Bonaiuto M.
        • Castaldo M.
        • Saitta C.
        • Cristadoro S.
        • Saitta A.
        Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesteremic sicilian individuals.
        Clin. Chem. 2004; 50: 2077-2082
        View in Article
        • Kiortsis D.N.
        • Tsouli S.
        • Lourida E.S.
        • Xydis V.
        • Argyropoulou M.I.
        • Elisaf M.
        • Tselepis A.D.
        Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia.
        Angiology. 2005; 56: 451-457
        View in Article
        • Iribarren C.
        • Gross M.D.
        • Darbinian J.A.
        • Jacobs Jr., D.R.
        • Sidney S.
        • Loria C.M.
        Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study.
        Arterioscler. Thromb. Vasc. Biol. 2005; 25: 216-221
        View in Article
        • Kardys I.
        • Oei H.H.
        • van der Meer I.M.
        • Hofman A.
        • Breteler M.M.
        • Witteman J.C.
        Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study.
        Arterioscler. Thromb. Vasc. Biol. 2006; 26: 631-636
        View in Article
        • Kardys I.
        • Oei H.H.
        • Hofman A.
        • Oudkerk M.
        • Witteman J.C.
        Lipoprotein-associated phospholipase A2 and coronary calcification. The Rotterdam coronary calcification study.
        Atherosclerosis. 2007; 191: 377-383
        View in Article
        • Iwasaki K.
        • Matsumoto T.
        • Aono H.
        • Furukawa H.
        • Samukawa M.
        Prevalence of noncalcified coronary plaque on 64-slice computed tomography in asymptomatic patients with zero and low coronary artery calcium.
        Can. J. Cardiol. 2010; 7: 377-380
        View in Article
        • Serruys P.W.
        • Garcia-Garcia H.M.
        • Buszman P.
        • et al.
        Effects of the direct lipoprotein-associated phospholipase A2 inhibitor Darapladib on human coronary atherosclerotic plaque.
        Circulation. 2008; 118: 1172-1182
        View in Article

      Article Info

      Publication History

      Published online: May 16, 2015
      Accepted: May 13, 2015
      Received in revised form: April 10, 2015
      Received: December 19, 2014

      Identification

      DOI: https://doi.org/10.1016/j.atherosclerosis.2015.05.006

      Copyright

      © 2015 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX